Leerink Partners Maintains Outperform on Guardant Health, Lowers Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners has maintained an 'Outperform' rating on Guardant Health but has lowered its price target from $60 to $50.
October 17, 2024 | 12:50 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Leerink Partners has maintained an 'Outperform' rating on Guardant Health but has lowered its price target from $60 to $50.
The 'Outperform' rating suggests continued confidence in Guardant Health's performance, but the lowered price target indicates some caution about its short-term potential. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100